The cholinergic receptor ligands: Nicotine (0.05, 0.1 mg/kg) (Tocris, Minneapolis, MN, USA), a cholinergic nicotinic receptor agonist, Scopolamine (1 mg/kg) (Tocris, USA), a cholinergic muscarinic receptor antagonist,
The CB2-receptor ligands: JWH 133 (0.25, 0.5, 1 mg/kg) (Tocris, USA), a potent selective CB2-receptor agonist, AM 630 (0.25, 0.5, 1 mg/kg) (Tocris, USA), a competitive CB2-receptor antagonist.
Cholinergic receptor ligands were dissolved in a saline solution (0.9% NaCl). In turn, CB2-receptor ligands were suspended in a 1% solution of Tween 80 (Sigma, St. Louis, MO, USA) in a saline solution. Nicotine was administered subcutaneously (s.c.), and Scopolamine and CB2-receptor ligands were administered intraperitoneally (i.p.) at a volume of 10 mL/kg. Fresh drug solutions were prepared on each day of experimentation. Control groups received injections of saline with Tween 80 at the same volume and by the same route of administration.
Experimental doses of cholinergic and CB2-receptor ligands used for behavioral experiments and procedures were chosen accordingly to those frequently used in literature and our previous experiences [6 (link),7 (link),12 (link),74 (link)].
Free full text: Click here